DongKoo Bio & Pharma Co., Ltd. (KOSDAQ: 006620)

DongKoo Bio & Pharma Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2017
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2017
Cash & Equivalents	12,190	15,713	12,514	19,557	4,881	9,910
Short-Term Investments	1,347	1,941	1,351	143.14	87.57	-
Trading Asset Securities	9,958	5,245	21,271	12,399	24,616	1,103
Cash & Short-Term Investments	23,495	22,898	35,136	32,100	29,585	11,013
Cash Growth	-17.30%	-34.83%	9.46%	8.50%	168.64%	121.89%
Accounts Receivable	20,221	19,879	18,503	15,774	17,455	20,952
Other Receivables	2,902	1,570	898.47	633.49	136.73	292.77
Receivables	25,237	22,449	19,402	16,408	17,592	21,245
Inventory	42,168	42,606	31,428	24,964	24,971	12,146
Prepaid Expenses	445.65	216.61	225.89	229.66	200.1	37.37
Other Current Assets	361.79	195.02	1,226	131.5	4.72	76.33
Total Current Assets	91,707	88,365	87,417	73,832	72,353	44,517
Property, Plant & Equipment	63,029	50,483	39,681	40,051	40,377	28,237
Long-Term Investments	54,459	39,800	33,619	35,498	26,495	1,759
Other Intangible Assets	14,192	10,903	9,010	3,048	2,081	975.1
Long-Term Accounts Receivable	-	-	-	-	16.66	-
Long-Term Deferred Tax Assets	915.86	291.5	6.95	-	-	-
Other Long-Term Assets	1,334	1,260	2,325	2,358	3,031	105.21
Total Assets	225,637	191,103	172,059	154,786	144,353	75,593
Accounts Payable	11,280	11,202	14,300	11,591	9,191	9,954
Accrued Expenses	10,758	10,274	9,637	6,496	4,683	3,623
Short-Term Debt	62,500	40,500	33,000	18,070	18,000	12,050
Current Portion of Long-Term Debt	-	-	-	5,000	-	564.53
Current Portion of Leases	716.34	842.63	567.83	453.23	523.99	-
Current Income Taxes Payable	2,264	1,638	2,576	1,978	915.59	1,807
Other Current Liabilities	10,928	8,863	5,963	6,434	7,194	6,582
Total Current Liabilities	98,446	73,318	66,044	50,022	40,508	34,580
Long-Term Debt	5,295	1,447	-	-	5,000	2,412
Long-Term Leases	881.2	1,014	754.22	770.27	219.01	-
Long-Term Deferred Tax Liabilities	-	4.5	140.93	2,315	3,034	785.4
Other Long-Term Liabilities	7,426	4,596	3,015	1,350	939.53	-
Total Liabilities	113,069	80,658	69,953	54,662	49,701	37,849
Common Stock	14,232	14,232	14,232	14,232	4,802	3,811
Additional Paid-In Capital	33,063	33,063	33,063	33,063	42,569	13,153
Retained Earnings	73,108	69,735	61,675	57,158	49,727	21,535
Treasury Stock	-9,056	-7,137	-7,058	-4,062	-2,065	-66.4
Comprensive Income & Other	1,090	507.18	193.39	-266.18	-380.89	-687.91
Total Common Equity	112,437	110,400	102,106	100,124	94,653	37,745
Minority Interest	132.12	44.92	-	-	-	-
Shareholders' Equity	112,569	110,445	102,106	100,124	94,653	37,745
Total Liabilities & Equity	225,637	191,103	172,059	154,786	144,353	75,593
Total Debt	69,392	43,804	34,322	24,294	23,743	15,026
Net Cash (Debt)	-45,897	-20,906	813.88	7,806	5,842	-4,013
Net Cash Growth	-	-	-89.57%	33.61%	-	-
Net Cash Per Share	-1665.79	-756.89	29.32	276.23	206.49	-178.66
Filing Date Shares Outstanding	27.3	27.61	27.62	28.04	28.29	22.79
Total Common Shares Outstanding	27.3	27.61	27.62	28.04	28.29	22.79
Working Capital	-6,739	15,046	21,374	23,811	31,844	9,938
Book Value Per Share	4118.28	3998.84	3696.33	3570.78	3345.63	1656.17
Tangible Book Value	98,245	99,497	93,096	97,076	92,572	36,770
Tangible Book Value Per Share	3598.47	3603.92	3370.16	3462.08	3272.08	1613.39
Land	13,262	10,849	10,849	10,584	10,584	10,584
Buildings	27,153	29,667	27,353	26,899	26,120	19,482
Machinery	7,014	19,768	17,741	17,813	16,838	10,009
Construction In Progress	10,314	10,694	1,451	887.9	844.54	40

Source: S&P Capital IQ. Standard template. Financial Sources.